{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028369","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.044985+00:00","generated_at":"2026-05-26T02:25:10.977494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval","bullets":["FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.","DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.","Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.","Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).","Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028369","json":"https://secwatch.observer/filing/0000950170-25-028369.json","markdown":"https://secwatch.observer/filing/0000950170-25-028369.md","text":"https://secwatch.observer/filing/0000950170-25-028369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/0000950170-25-028369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025028369/dyn-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:25:10.977494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}